 |
Twentyeight-Seven Therapeutics
Last updated: July 31, 2025
Kazumi Shiosaki, CEO
USA | Funding: $80M (+)
Website: https://www.twentyeight-seven.com/
Twentyeight-Seven develops small molecules that can modulate levels of miRNAs by targeting proteins that interact with these miRNAs.
Website: https://www.twentyeight-seven.com/
Twentyeight-Seven develops small molecules that can modulate levels of miRNAs by targeting proteins that interact with these miRNAs.
